Date:
April 18, 2022
Issue #:
1648
Summary:
Efgartigimod alfa-fcab (Vyvgart – Argenx), a first-in-class neonatal Fc receptor (FcRn) antagonist,
has been approved by the FDA for IV treatment of
generalized myasthenia gravis in adults who are
anti-acetylcholine receptor (AChR) antibody positive.
The IV complement inhibitor eculizumab (Soliris) was
approved for the same indication in 2017.
has been approved by the FDA for IV treatment of
generalized myasthenia gravis in adults who are
anti-acetylcholine receptor (AChR) antibody positive.
The IV complement inhibitor eculizumab (Soliris) was
approved for the same indication in 2017.